Titre :
  • EORTC 10941: A phase II study of liarozole in postmenopausal patients with 'chemotherapy-resistant' or 'potentially hormone sensitive' metastatic breast cancer.
Auteur : Hamilton, Andrew ; Roy, J A ; Beex, Louk ; Piccart-Gebhart, Martine ; Mauriac, L ; Coleman, R ; Paridaens, Robert ; Boes, G H ; Van Vreckem, A ; Palmer, P ; Klijn, J
Informations sur la publication : Breast cancer research and treatment, 60, 2, (page 181-188)
Statut de publication : Publié, 2000-03
Sujet CREF : Sciences bio-médicales et agricoles
Mots-clés MeSH : Adult
Aged
Antineoplastic Agents, Hormonal -- adverse effects
Antineoplastic Agents, Hormonal -- pharmacology
Antineoplastic Agents, Hormonal -- therapeutic use
Breast Neoplasms -- chemistry
Breast Neoplasms -- drug therapy
Breast Neoplasms -- pathology
Disease-Free Survival
Drug Resistance, Neoplasm
Female
Humans
Imidazoles -- adverse effects
Imidazoles -- pharmacology
Imidazoles -- therapeutic use
Middle Aged
Postmenopause
Receptors, Estrogen -- analysis
Treatment Outcome
Note : Clinical Trial
Clinical Trial, Phase II
Journal Article
Multicenter Study
Research Support, Non-U.S. Gov't
Langue :
  • Anglais
Identificateurs : urn:issn:0167-6806 
info:pmid/10845281